McDonald's, ON Semiconductor And 3 Stocks To Watch Heading Into Monday
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 10 2025
0mins
Source: Benzinga
Earnings Reports Anticipated: Major companies like McDonald's, ON Semiconductor, Rockwell Automation, and Vertex Pharmaceuticals are expected to report their quarterly earnings today, with varying projections for revenue and earnings per share.
Stock Performance Overview: In after-hours trading, shares of McDonald's, ON Semiconductor, VOXX International, Rockwell Automation, and Vertex Pharmaceuticals experienced slight declines ahead of their earnings announcements.
Analyst Views on VRTX
Wall Street analysts forecast VRTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRTX is 482.53 USD with a low forecast of 401.00 USD and a high forecast of 575.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
14 Buy
8 Hold
0 Sell
Moderate Buy
Current: 438.920
Low
401.00
Averages
482.53
High
575.00
Current: 438.920
Low
401.00
Averages
482.53
High
575.00
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
